UNAIDS urges global access to new HIV drug Lenacapavir

UNAIDS welcomes Gilead Sciences' successful trial results for Lenacapavir, a long-acting HIV medicine for Pre-Exposure Prevention. The trial showed high efficacy in preventing HIV infections, prompting UNAIDS to urge equitable global access. Concerns arise over Gilead's access strategy for low and middle-income countries, lacking mention of upper-middle-income countries and the Medicines Patent Pool. UNAIDS emphasizes the importance of ensuring access to all who need it to end AIDS by 2030.